Skip to main content
OpenTrials
Completed

NCT Number: NCT02860702

Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology

A randomized, blinded, controlled trial to evaluate growth velocity and clinical outcomes in infants with single ventricle physiology fed an exclusive human milk diet prior to, and throughout the post-operative period following, surgical repair. Human milk is defined as expressed human milk or donor milk and its derivatives, human milk-based fortifier and human milk caloric fortifier.

The study hypothesis is that infants fed an exclusive human milk diet will have short and long term benefits, with improved wound healing, growth, and neurodevelopmental outcomes while reducing episodes of feeding intolerance and necrotizing enterocolitis (NEC).

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 day–7 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Loma Linda University, Loma Linda, California, United States

Loading trial locations.

About this study

This is a single blinded (physician investigator), randomized, controlled trial to evaluate growth velocity and clinical outcomes in infants with single ventricle physiology fed an exclusive human milk diet during their initial hospitalization after birth and through the 30 days post-surgical repair feeding period or hospital discharge, whichever comes first.

Subjects will be randomized to one of two groups at birth or immediately following diagnosis if prenatal care was not obtained prior to birth. Parents who decline participation by their infants in the study will be asked to consent to data gathering on their infants who will be treated and fed per institutional practice. The data on these individuals will be summarized and evaluated descriptively in comparison with the actual trial results.

All patients will receive exclusive maternal human milk or donor human milk prior to randomization. Once randomized, patients in Group One will receive an exclusive human milk diet prior to the surgery and throughout the 30-day feeding period following surgical repair or until hospital discharge, whichever comes first. Day 1 is defined as the day of the first enteral feed post-surgery. Patients in Group Two (Control Group) will receive maternal human milk or formula or donor human milk (per standard of care at each hospital) in the pre-surgical period. In the post-surgical period the control group will receive human milk or formula, as per feeding algorithm The primary objective of this study is to evaluate growth velocity (weight velocity [g/kg/day] and weight z-score from World Health Organization (WHO) growth charts) at 30 days after the initiation of feed post-surgery for infants with single ventricle physiology who are fed an exclusive human milk diet from birth through the 30 day feeding period following surgical repair or until hospital discharge, whichever comes first.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Term infants (≥37 and 0/7 weeks gestational age) ≤ 7 days old with a diagnosis of single ventricle physiology who are thought to require a single ventricle repair at the time of enrollment.
  • Infant feeding was NPO or consisted of 100% human milk diet prior to enrollment
  • Parent(s) willing to sign informed consent.
  • Parent(s) willing to comply with study follow-up procedures.
  • Require surgical palliation within the first 1 month of life.

Exclusion criteria

  • Term infants >7 days old at the time of diagnosis.
  • <37 weeks gestation
  • Infants requiring cardio-pulmonary resuscitation prior to surgical repair.
  • Outborn infants who received enteral nutrition at the other institution prior to surgical repair. If it is uncertain if infant received even 1 bottle or a small amount of formula, infants will be excluded.
  • Major congenital abnormalities that could significantly affect survival such as:
  • Confirmed or suspected major genetic abnormalities (lethal or with extremely low probability for survival).
  • Chromosomal abnormalities: Trisomies (13, 18, 21 etc.) deletions or translocations (Turner/Williams Syndrome, DiGeorge, to name a few)
  • Major organ system abnormalities not related to a genetic syndrome that are lethal or have extremely low probability for survival (i.e, bilateral kidney intrinsic disease, pulmonary hypoplasia, Central Nervous System (CNS) malformations: Arnold Chiari, myelomeningoceles, hydranencephaly, schizencephaly, holoprosencephaly))
  • Heterotaxia
  • Metabolic disorders affecting growth: homocystinuria, methylmalonic acidemias, propionic acidemias, urea cycle defects
  • Evidence of intracerebral hemorrhage (IVH) ≥ Grade 3
  • Any comorbidity or significant clinical event prior to enrollment, deemed by the Investigator as likely to affect survival.
  • Requires Extracorporeal Membrane Oxygenation (ECMO) pre-operatively
  • Legally Authorized Representative(s) unwilling to comply with an exclusive human milk diet either in the form of mother's milk, human milk-based human milk fortifier, human milk based caloric fortifier or donor human milk during the initial hospitalization period and through the 30 day feeding period after surgical repair or hospital discharge, whichever comes first.

Treatment and study plan

Human Milk Derived Fortifier

Other

Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm

Human/Bovine Milk

Other

Bovine milk derived fortification

Other names: Human/Formula Milk

Primary outcomes

  1. growth velocity

    Time frame: 30 days

    weight velocity in g/kg/day

  2. growth velocity

    Time frame: 30 days

    weight z-score 30 days post 1st operation

Secondary outcomes

  1. linear growth rate

    Time frame: 6 months

    cm/week

  2. linear growth rate

    Time frame: 6 months

    z-score

  3. head circumference growth rate

    Time frame: 6 months

    cm/week

  4. head circumference growth rate

    Time frame: 6 months

    z-score

  5. Feeding Intolerance

    Time frame: 30 days

    defined as nil per os (NPO) for at least 24 in the 30 days of post-surgery enteral feeding period (day 1 is the first day of feeding post-op), NPO due to elective surgeries or procedures will not be defined as feeding intolerance.

  6. Length of stay

    Time frame: up to 24 months

    time hospitalized after 1st surgery

  7. Sepsis

    Time frame: 30 days

    Sepsis 30 days post 1st operation

  8. Necrotizing enterocolitis

    Time frame: 30 days

    NEC 30 days post 1st operation

  9. wound infections

    Time frame: 30 days

    wound infection 30 days post 1st operation

  10. wound dehiscence

    Time frame: 30 days

    wound dehiscence 30 days post 1st operation

  11. parenteral nutrition

    Time frame: 30 days

    in days, during the 30 day post 1st operation

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center at San Antonio

Other

Collaborators

  • Ann & Robert H Lurie Children's Hospital of Chicago
  • Baylor College of Medicine
  • Children's Hospital Medical Center, Cincinnati
  • Children's Hospital of Orange County
  • Columbia University
  • Cook Children's Medical Center
  • Prolacta Bioscience
  • University of Florida
  • University of Oklahoma
  • University of Texas

Registry information

Official study title

A Randomized Controlled Trial to Evaluate Growth Velocity and Clinical Outcomes of Infants With Single Ventricle Physiology Fed an Exclusive Human Milk Diet With Early Nutritional Fortification Following Surgical Repair

Important dates

Study start
2016
Primary completion
2020
Study completion
2022
First posted
Aug 9, 2016
Registry last updated
Sep 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.